13. Restructuring Costs (Notes)

9 Months Ended

Sep. 30, 2019

Restructuring Costs [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded less than $0.1 million and $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and nine months ended September 30, 2019, respectively. The amounts recorded were reflected in Cost of goods sold of $(0.1) million in the Condensed Consolidated Statements of Income for the nine months ended September 30, 2019. From May 2016 to September 30, 2019, total expenses were $12.7 million. The liability of $0.7 million as of September 30, 2019 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets, and is expected to be paid or adjusted by the end of 2019.

Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded less than $0.1 million and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From December 2017 to September 30, 2019, total expenses were $21.4 million.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded no adjustments and $(0.3) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From June 2018 to September 30, 2019, total expenses were $1.4 million.

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded no adjustments and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From December 2018 to September 30, 2019, total expenses were $4.1 million.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of zero and $(0.2) million, and in Research and development expense of zero and $(0.1) million in the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2019, respectively. The liability of $3.5 million as of September 30, 2019 consisted of $1.4 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.9 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

Balances as of December 31, 2018:	$	11.5
Adjustment to expense	(0.3		)
Cash payments	(7.4		)
Foreign currency translation gains	(0.3		)
Balances as of September 30, 2019:	$	3.5